A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $125 to $150
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $102 to $130
Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Envista Holdings (NVST) and Hologic (HOLX)
Blueprint Medicines Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)
Blueprint Medicines Is Maintained at Buy by Needham
Blueprint Medicines Analyst Ratings
Needham Maintains Buy on Blueprint Medicines, Lowers Price Target to $130
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Cuts Target Price to $130
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $100
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)
Wedbush Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Raises Target Price to $128
Wedbush Reiterates Outperform on Blueprint Medicines, Maintains $128 Price Target
Blueprint Medicines (BPMC) Receives a Buy From Wedbush
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $133
Blueprint Medicines Analyst Ratings
Wolfe Research Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $132